Joint Venture company for hydrogen storage, transport and supply, based on Hydrogenious LOHC Technologies’ Liquid Organic Hydrogen Carrier (LOHC) technology Financial commitment of both parties for build-up of industrial-scale LOHC plants in Germany/North-Rhine Westphalia (Chempark Dormagen) and Netherlands/Rotterdam (both in permitting and preparatory phase) Vopak and Hydrogenious LOHC Technologies will incorporate an equal shared joint venture, named LOHC Logistix, for hydrogen storage, transport and supply based on Hydrogenious’ Liquid Organic Hydrogen Carrier (LOHC) technology. This is one of the major steps both companies have agreed on recently to push LOHC market solutions and large-scale pilot projects forward. Hydrogen is expected to play a dominant role in future energy systems. When it comes to handling the volatile hydrogen gas, the LOHC technology developed by Hydrogenious has a big potential to help speed up the development of an international hydrogen market. The LOHC pioneer from Germany uses the thermal oil benzyl toluene as liquid organic hydrogen carrier (LOHC-BT), which is already well-established in the industry as a heat transfer medium and has ideal properties for safe handling in ports. Due to its characteristics as a flame retardant and non-explosive carrier with a high volumetric energy density, benzyl toluene can be handled like a fossil liquid fuel within existing infrastructure, tankers and vehicles at ambient pressure and temperature, making it a natural fit with current port infrastructure and fleet of vessels, railcars, and tank trucks. After the release of hydrogen (dehydrogenation), the LOHC can be reused to bind hydrogen many hundreds of times. Hydrogenious LOHC Technologies has sold pilot-scale LOHC systems to partners in several countries like Finland, Germany and the US over the last years and has implemented the first full LOHC supply chain for hydrogen mobility this summer. Hydrogenious supplies the Hydrogen Refueling Station Erlangen in Germany via LOHC, which is a worldwide novelty. The joint venture LOHC Logistix GmbH located in Germany will support both parties to facilitate their efforts to supply green hydrogen to off-takers, using LOHC based transportation via ship, train, tanker, etc. The incorporation of the joint venture is subject to customary closing conditions. For transportation and supply, it will purchase hydrogenation as well as dehydrogenation services from/at the respective LOHC plant operating companies and organize transport. Moreover, the two partners committed themselves to accelerate the establishment of the LOHC storage plant planned at Chempark Dormagen (Germany/North-Rhine Westphalia), for which the kick-off has been given in 2021 (link), as well as a release plant in Rotterdam with a release capacity of 1.5 tonnes of hydrogen per day. The intention of both parties is to accelerate the scale up. Vopak became involved as a strategic investor in Hydrogenious LOHC Technologies in 2019 (with a shareholding of around 10%). Today's announcement is connected with Hydrogenious' as well as Vopak’s first equal investment in the new joint venture and a convertible loan by Vopak to Hydrogenious which can be converted into an equity stake following future funding rounds by Hydrogenious in the upcoming years. Dr Daniel Teichmann, founder and CEO at Hydrogenious LOHC Technologies "Worldwide there exists a huge capacity of storage tanks, sea vessels, inland tankers and tank trucks for the storage and transportation of liquid fossil fuels. Hydrogenious wants to turn all this valuable infrastructure into the hydrogen infrastructure of the future using our LOHC technology. Ever since Vopak’s investment in our company we have worked very closely together in developing and establishing clean hydrogen value chains. With the build-up of LOHC plants in Chempark Dormagen and Rotterdam we will establish a green hydrogen supply chain that we see as a blueprint for a future even more comprehensive network across Europe and the Middle East and beyond. As a great start into the new year, we are proud to announce this new partnership with Vopak and the foundation of our Joint Venture. As a team we work together to further accelerate the establishment of a clean hydrogen infrastructure in order to 'carry the new energy world', as our corporate claim says.” Dick Richelle, Chairman Executive Board and CEO Vopak "This investment is well in line with Vopak's strategy to accelerate its portfolio investments towards new energies and sustainable feedstocks. We believe that different types of hydrogen logistics need to be developed to be able to facilitate the needed future flows of hydrogen and hydrogen carriers. We are excited to work together with Hydrogenious to jointly develop the first industrial scale hydrogen supply chain using LOHC." About Royal Vopak Royal Vopak is the world’s leading independent tank storage company. We store vital products with care. Products for everyday life. The energy that allows people to cook, heat or cool their homes and for transportation. The chemicals that enable companies to manufacture millions of useful products. The edible oils to prepare food. We take pride in improving access to cleaner energy and feedstocks for a growing world population, ensuring safe, clean and efficient storage and handling of bulk liquid products and gases at strategic locations around the world. We are excited to help shape a sustainable future by developing infrastructure solutions for new vital products, focusing on zero- and low-carbon hydrogen, ammonia, CO2, long duration energy storage and sustainable feedstocks. We have a track record of over 400 years in navigating change and are continuously investing in innovation. On sustainability, we are ambitious and performance driven, with a balanced roadmap that reflects key topics that matter most to our stakeholders and where we can have a positive impact for people, planet and profit and the United Nations Sustainable Development Goals. Vopak is listed on the Euronext Amsterdam and is headquartered in Rotterdam, the Netherlands. For more information, please visit www.vopak.com About Hydrogenious LOHC Hydrogenious LOHC adds the missing link to high-performing hydrogen value chains globally. Based on its proven Liquid Organic Hydrogen Carrier (LOHC) technology with benzyl toluene as carrier medium, Hydrogenious LOHC allows for superior, flexible hydrogen supply to consumers in industry and mobility across the globe, utilizing conventional liquid-fuel infrastructure. Founded in 2013, the portfolio of the market-leading pioneer and its joint venture companies today includes stationary and mobile (on-board) LOHC-based applications: Hydrogenious LOHC Technologies, headquartered in Erlangen/Germany, offers – within an EPC partnership with Bilfinger – (de-)hydrogenation turnkey plants, Operation & Maintenance and LOHC logistics services – ensuring safe, easy and efficient hydrogen storage, transport and distribution. Hydrogenious LOHC Emirates, based in the United Arab Emirates and a joint venture with Emirates Specialized Contracting & Oilfield Services (ESCO), acts as the regional spearhead in the Middle East since the end of 2021. Hydrogenious LOHC Maritime, established in 2021 jointly with Østensjø Group and located in Norway, develops an emission-free onboard propulsion system with a promising LOHC/fuel cell solution for the global shipping industry. With its >180 staff members and investors AP Ventures, Royal Vopak, Winkelmann Group, Mitsubishi Corporation, Covestro, JERA Americas, Temasek, Hyundai Motor Company, Chevron Technology Ventures and Pavilion Capital, Hydrogenious LOHC is a major enabler and accelerator for the energy transition. www.hydrogenious.net | www.hydrogenious-emirates.ae | www.hydrogenious-maritime.net For more information please contact: Vopak Press: Liesbeth Lans - Manager External Communication global.communication@vopak.com Analysts and Investors: Fatjona Topciu - Head of Investor Relations investor.relations@vopak.com Media contacts Hydrogenious LOHC Birka Friedrich, Head of Corporate Communications and Marketing birka.friedrich@hydrogenious.net Frank Erik Walter, Global Media Relations & PR frank.walter@hydrogenious.net

Zum Abschluss des ersten ELSA-Programms gab es die Life Science Pitch Bowl im Sartorius Quartier Göttingen, organisiert von der Life Science Factory. Der Entrepreneurial Life Science Accelerator, kurz ELSA, wurde von der Life Science Factory, Fraunhofer AHEAD und Helmholtz München initiiert und beinhaltet gemeinsame Veranstaltungen und Coaching der Netzwerkorganisationen. In diesem Jahr startete der Entrepreneurial Life Science Accelerator, kurz ELSA, der von der Life Science Factory Göttingen, Fraunhofer AHEAD und Helmholtz München entwickelt wurde. Erstmals erhielten damit innovative Start-ups und Life-Sciences-Projekte von diesen drei Institutionen gemeinsam Unterstützung. Zum Abschluss des Programms fand am 15. Dezember ein Pitch-Event vor der Expertenjury und Publikum statt, bei dem das Start-up Advylop als Gewinner gekürt wurde. Das Siegerteam kann sich über weitere Coachingstunden freuen. Seit September werden in einem maßgeschneiderten Programm unter anderem die Bereiche Life-Sciences-Markt, Industrie und Go-to-Market an drei zweitägigen Workshops behandelt. Im Mittelpunkt stehen dabei 1:1-Coachings mit Experten zu individuellen Themen wie Finanzierungsmodelle, IP oder Pitches. Über einen Zeitraum von vier Monaten hatten die Teams damit die Gelegenheit, ihre Ideen im Austausch intensiv weiterzuentwickeln, ihre Geschäftsmodelle zu schärfen und Zugang zu Fachwissen und Finanzierung durch zielgruppenorientierte Pitches zu erhalten. „Der Bedarf an Unterstützung ist im Bereich der Life Science Start-ups hoch und sehr individuell. Das Programm hilft den teilnehmenden Start-ups unmittelbar durch die Fachexpertise der Partner und Branchenexperten. Durch exklusive Einzel-Sessions können wir sehr bedarfsorientiert agieren und jedem Start-up den Support bieten, den es gerade benötigt”, erklärt Sten Küster, Program & Event Manager der Life Science Factory, die Zielsetzung von ELSA. Und auch die teilnehmenden Start-ups zeigten sich vom Programm überzeugt: „Besonders begeistert hat mich der fortlaufende Austausch mit den Experten, und dass ich so mein Netzwerk ausbauen konnte. Ich konnte so meine Geschäftsidee klarer herauszukristallisieren und mir wurde klar, wie Biotech-Innovationen in Deutschland funktionieren”, resümiert Virginie Clement-Schatlo, Projektleiterin beim Göttinger Start-up GliTTher (Glioma Targeted Therapy). Benjamin Pardowitz vom Berliner Medtech-Start-up Roowalk nimmt eine Reihe von Erkenntnissen aus den vier Monaten mit: „Ich bin dankbar für die hilfreichen Praxis-Einblicke in frühe Phasen der Produktentwicklung von Medizinprodukten, Themen bei der Zulassung, zu den möglichen Finanzierungen und die Einblicke in Exit-Stories anderer Medtech-Firmen durch die erfahrenen Coaches. Zu realisieren, wo die Lücke zwischen Theorie und Praxis klafft, war ein enormes Learning für mich. Insbesondere das Wissen, dass für frühphasige Start-ups nicht unbedingt VCs die passenden ersten Finanzierungspartner sein müssen, nehmen wir für unsere weitere Planung des Produkts mit.” Quelle: transkript.de

Offenbach am Main, December 16, 2022 - Before the year’s close, we share bright news for the future city of Offenbach: The biotechnology company BioSpring is purchasing an area of over 30,000 square meters on the Innovation Campus for three additional production units—a move that may create as many as 1,500 new jobs. This addition comes after a decision last January to build a high-tech production facility on their one-hectare site on Kettelerstrasse. Combined with the three additional production units on Mühlheimer Strasse, BioSpring will be tripling their space on the Innovation Campus. In the booming biotechnology sector, BioSpring is one of Hesse's flagship companies. Started in 1997 with only six employees, the company, led by the two managing partners Dr. Sylvia Wojczewski and Dr. Hüseyin Aygün, already employs almost 500 people. Biospring manufactures active ingredients for the pharmaceutical and biotech industries and is a global leader in the production of synthetic DNA and RNA fragments, also known as oligonucleotides, for therapeutic drug applications, including cancer therapies and metabolic diseases. Due to BioSpring’s enormous growth, BioSpring was named the Hesse champion in the job engine category in 2021. In the long term, BioSpring will invest hundreds of millions into Offenbach. When completed, the Innovation Campus will host the world's largest capacities for special oligonucleotide-based active ingredients. Mayor Dr. Felix Schwenke emphasizes the enormous significance of the company's fundamental decision to expand strongly in Offenbach: "Offenbach will thus become an important production site for a very successful company in the biotech sector. Active ingredients based on the oligonucleotides produced by BioSpring have the potential to enable new therapeutic approaches for a large number of previously untreatable diseases. One of my central economic policy goals, to make Offenbach less dependent on individual industries by bringing in a broader mix of different companies, will thus become a reality in the coming years." Managing Director Sylvia Wojczewski: "We are very pleased that this expansion space in Offenbach will allow us to fully exploit our enormous growth potential in the coming years. For BioSpring, the purchase of this industrial site is a big step in shaping our future." BioSpring expects up to 200 new jobs to be created in Offenbach on the Kettelerstrasse site alone, which was acquired in January. To accomplish this, the company will repurpose the former social building of Farbwerke Hoechst, replacing the adjoining former worker’s canteen with a modern production facility. According to Managing Director Hüseyin Aygün, both the newly acquired site on Mühlheimer Strasse and the site on Kettelerstrasse, will provide space for up to 1,500 future-proof jobs for highly-qualified employees. Construction activities are scheduled to start in 2026/2027. The current production and laboratory facilities in Frankfurt-Fechenheim will be retained and expanded. A larger part of the administration, which will also be expanded by then, will be located in Offenbach in the long term. Substantial increase in production The significant expansion will provide the opportunity for BioSpring to increase its production capacities up to 30 times the current capacities long term, according to Hüseyin Aygün. This would enable highly innovative active ingredients to be produced in Offenbach on a multi-ton scale in the future. Hüseyin Aygün: "Furthermore, the quality control and analytics divisions in Offenbach are being massively expanded. New product and service lines are being created. We are sending a strong signal for innovative and future-oriented active ingredient production at the German site." "Offenbach's strategy for attracting innovative companies is bearing fruit," Sylvia Wojczewski attests to the City. "We are very happy about the conclusion of the purchase agreement with the municipal utility company INNO." This was preceded by intensive discussions at the highest level between Offenbach's city leaders concerning Mayor Dr. Felix Schwenke and the management of the biotech company. Sylvia Wojczewski praised the "excellent support provided by the City of Offenbach" and the "rapid process". "For me as treasurer, such days are of course also gratifying," says city treasurer Martin Wilhelm. "With the settlement of Frankfurt-based valve manufacturer Samson AG, one of the world's leading suppliers of intelligent control valves, and the biotech company BioSpring, which is also one of the world's leading companies in its sector, there will again be a high level of value created for the city in the form of business tax revenue and jobs in the foreseeable future." "However, it is important to understand," Wilhelm said, "that it will now take several more years for such days to be noticeable, not only through excavators and construction work, but also in the city coffers, which are important to citizens." This in no way dims the joy, it is just important to keep in mind. "You simply have to acknowledge the facts" adds city planning officer Paul-Gerhard Weiss: "After less than five years of work by Lord Mayor Felix Schwenke, very important foundations have been laid for a substantially better future for Offenbach—Prospects that this city has not had for decades." Meanwhile, the City is working at full speed on the development plan for the Innovation Campus. Weiss continued: "The urban land use planning procedure is currently in the drafting phase, including the preparation of all necessary expert opinions and concepts." For example, the procedure is concerned with the external and internal traffic development, an innovative mobility concept and a parking space key based on it, as well as energy and ecological issues such as solar panels or roof and façade greening. To this end, an energy concept, a climate report, and an environmental report will be drawn up. It is expected that the city council will be able to pass an approval resolution on the public display of the B-Plan in the spring, according to Councilor Weiss. Lord Mayor Schwenke summarizes: "I have very great respect for the personal performance of the management, Dr. Wojczewski and Dr. Aygün, and I am very grateful for the good cooperation. We are offering the company the opportunity to continue its success story on its own land and to grow considerably. As long as it succeeds, it is good for people's health, for the company and for the City. If Samson and BioSpring's plans work out, there may be more people working on the Innovation Campus in the near future than in the heyday of the postwar decades. In this respect, today is without a doubt a very good day for Offenbach." Schwenke also expressly emphasized the outstanding support for this project, including from Mayor Sabine Gross, who is currently on vacation. 70 percent of the campus marketed The owner of the Innovation Campus is INNO Innovationscampus GmbH & Co. KG, a real estate company owned by Stadtwerke Offenbach, which is developing and marketing the site together with its sister company OPG Offenbacher Projektentwicklungsgesellschaft mbH on behalf of the city. "26 hectares of the campus are available for commercial development," explains Daniela Matha, who is responsible for the entire real estate division at Stadtwerke and manages the INNO company together with Stadtwerke CEO Peter Walther. "More than 18 hectares, 70 percent of the developable area, have now been sold," says Matha, pleased with the rapid marketing success. More than half of this, 14.3 hectares, was acquired by Samson AG last year. BioSpring will initially set up its production as planned on just under one hectare in the east of the campus, directly next to Samson, and then expand on the newly acquired three-hectare site in the south of the industrial park. BioSpring BioSpring is a contract manufacturer for the biotech and pharmaceutical industries and a global leader in the production and analysis of oligonucleotides, which are used in medicine, diagnostics, and research. Oligonucleotides are made up of the same building blocks as human genetic material. BioSpring is the most important international manufacturer, especially for the therapeutic production of so-called gene scissors, which are used for the revolutionary "genome editing" as a novel treatment option. BioSpring was founded in Frankfurt am Main by Dr. Hüseyin Aygün and Dr. Sylvia Wojczewski, who were students at Goethe University at the time, and is still owner-managed today. The company, which now has almost 500 employees, has its production headquarters in Frankfurt-Fechenheim and a subsidiary in San Diego, USA. The active ingredients produced at BioSpring have the potential to provide therapies for a wide range of diseases that are currently untreatable. These include novel active ingredients for the treatment of cardiovascular and metabolic diseases as well as cancer, for example. Contact Dr. Martin Schink, Senior Team Lead Marketing BioSpring Gesellschaft für Biotechnologie mbH Alt-Fechenheim 34, 60386 Frankfurt am Main Telefon: +49 (0) 69 66055000 E-Mail: schink@biospring.de